Despite dramatic impact during Covid19 outbreak, Pharma and MedTech are expected to be relatively protected on the long run, particularly versus transportation or oil industries. However, the commercial re-start will require significant adaptations to an environment that looks dramatically different. Now is the time to create a re-start plan. Top priorities should include defining a detailed relaunch map, reviving demand and capture pockets of profitable growth should be among top priorities. Helping Pharma and MedTech build a re-start plan and adapted GoToMarket is one the specialties of BlueJet Consulting. Contact us now for a free diagnosis. #postcovid19 Continue reading
